Person:
DİNÇ, HARİKA ÖYKÜ

Profile Picture
Google ScholarScopusORCIDPublons
Status
Kurumdan Ayrılmıştır.
Organizational Units
OrgUnit Logo
Organizational Unit
Job Title
First Name
HARİKA ÖYKÜ
Last Name
DİNÇ
Name
Email Address
Birth Date

Filters

2020 - 20223
Reset filters

Settings

Type: Article × Subject: SARS-CoV-2 ×

Search Results

Now showing 1 - 3 of 3
  • Thumbnail Image
    PublicationOpen Access
    Anti-SARS-CoV-2 IgG and Neutralizing Antibody Levels in Patients with Past COVID-19 Infection: A Longitudinal Study.
    (2022-04-05T00:00:00Z) Dinç, HARİKA ÖYKÜ; Demirci, Mehmet; Özdemir, Yusuf Emre; Sirekbasan, Serhat; Aktaş, Ayse Nur; Karaali, Rıdvan; Tuyji Tok, Yeşim; Özbey, Doğukan; Akçin, Rüveyda; Gareayaghi, Nesrin; Kuşkucu, Mert Ahmet; Midilli, Kenan; Aygün, Gökhan; Sarıbaş, Suat; Kocazeybek, Bekir; DİNÇ, HARİKA ÖYKÜ
    Background: Monitoring the longevity of immunoglobulin G (IgG) responses following severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infections is vital to understanding the role of antibodies in preventing infection. Aims: To determine the quantitative IgG responses specific to the Spike-S1 (S1) receptor-binding domain (S1/RBD) region of the virus in serum samples taken between 4 weeks and 7 months after polymerase chain reaction (PCR) positivity in patients who are diagnosed with coronavirus disease-2019 (COVID-19). Study design: A longitudinal study. Methods: This study included 113 patients with a clinical and molecular diagnosis of COVID-19. The first and second serum samples were taken 1 and 7 months, respectively, after the PCR positivity. S1/RBD-specific IgG antibody response was assayed using anti-SARS-CoV- 2 QuantiVac ELISA (IgG) kit (Euroimmun, Lübeck, Germany). The neutralizing antibodies were investigated in 57 patients whose IgG test results were above the cut-off value. Results: In 57 patients with SARS-CoV-2 IgG, the anti-SARS-CoV-2 IgG quantitative antibody levels significantly decreased after 7 months (Z = −2.197, p = 0.028). A correlation was detected between the anti-SARS-CoV-2 IgG and nAb percent inhibition (IH%) levels detected in 1 month (rs = 0.496, p < 0.001), but without significant correlation in serum samples taken on 7 months. The nAb IH% levels of the first and second were compared for COVID-19 severity and revealed no statistical difference (p = 0.256). In the second serum sample, the nAb IH%s of patients with moderate COVID-19 showed a statistically significant difference from patients with mild COVID-19 (p = 0.018), but without significant differences between severe and moderate or mild COVID-19. Conclusion: SARS-CoV-2 quantitative IgG antibody titers are significantly reduced at long-term follow-up (> 6 months). Due to the limited information on seroconversion, comprehensive studies should be conducted for long-term follow-up of the immune response against SARS-CoV-2.
  • Thumbnail Image
    PublicationOpen Access
    [Evaluation of the Diagnostic Performance of SARS-CoV-2 Rapid Antigen Tests in COVID-19 Patients].
    (2022-04-01T00:00:00Z) Tuyji Tok, Yeşim; Dinç, HARİKA ÖYKÜ; Akçin, Rüveyda; Daşdemir, Ferhat Osman; Eryiğit, Önder Yüksel; Demirci, Mehmet; Gareayaghi, Nesrin; Kuşkucu, Mert Ahmet; Kocazeybek, Bekir Sami; DİNÇ, HARİKA ÖYKÜ
    The gold standard in the definitive diagnosis of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is nucleic acid amplification tests (NAAT) due to their high sensitivity and specificity in detecting viral ribonucleic acid. However, while leaving two years behind in the pandemic, resources have come to the point of exhaustion in terms of both the economy and the manpower working in the field of health services. Therefore, the need for rapid, simple and accurate tests to diagnose SARS-CoV-2 infection continues. In this study, it was aimed to compare the performance characteristics of SARS-CoV-2 rapid antigen tests (RAgT) in the diagnosis of coronavirus disease 2019 (COVID-19) cases with the real-time reverse transcription-polymerase chain reaction (rRT-PCR) method. In Istanbul University-Cerrahpaşa Faculty of Medicine COVID-19 Molecular Diagnosis Laboratory, SARS-CoV-2 RNA positive respiratory tract samples with viral loads of <25 Ct (cycle of treshold), 25-29 Ct, 30-35 Ct and 35
  • Thumbnail Image
    PublicationOpen Access
    SARS CoV-2 Pathogenesis and Immune Response
    (2020-12-01T00:00:00Z) Dinç, Harika Öykü; Yüksel Mayda, Pelin; DİNÇ, HARİKA ÖYKÜ; YÜKSEL MAYDA, PELİN
    The agent responsible for the epidemic that first appeared in Wuhan, China, in December 2019 was detected to be the new coronavirus (2019-nCoV). Later, the virus that caused respiratory tract infection was discovered to be a member of the beta-coronavirus family, it was named as severe acute respiratory syndrome-CoV2 (SARS-CoV 2), and the disease it caused was called CoV infection disease-19 (COVID-19). The epidemic started in China, spread rapidly first to East Asian countries, then Europe and America, affected the whole world, and was declared a pandemic by the World Health Organization. This review presents an overview of SARS-CoV2 and aims to examine its intracellular pathogenesis and host immune responses.